Mirvetuximab Soravtansine and its TreatmentAssociated Ocular Adverse Effects. A Review of the Current Knowledge

Overview

Mirvetuximab soravtansine is an antibody–drug conjugate targeting folate receptor alpha (FRα), which is used in the treatment of platinum-resistant ovarian cancer. Its administration is associated with a distinct spectrum of ocular adverse events, representing a clinically relevant limitation of therapy. The most common manifestations include keratopathy, blurred vision, and dry eye symptoms. These effects are generally reversible and manageable upon appropriate ophthalmologic monitoring. This review summarizes the current knowledge regarding the mechanisms, clinical presentation, incidence, prevention, and management of mirvetuximab-associated ocular toxicity.

Keywords:

ovarian cancer – Cornea – mirvetuximab soravtansine – ADC – keratopathy – ocular adverse events